LOL Contrave increases blood pressure. After VVUS panel's comment on QNEXA's increase in heart rate, everyone knows Contrave will get slammed on cardio safety. If ARNA went up because Lancet's editorial published yesterday dissed Contrave, OREX would have gapped down and ARNA should have gapped up. Its certainly not the case. ARNA is just trading on momentum now. I am not complaining here since I have always been bullish on Lorcaserin's potential for diabetics rather than obesity. In fact, I am probably going to bet big money on Bloom-DM data.
Serotonin 2C agonists have been shown to be quite effective in treating diabetic mice, and the MOA is not just through weight loss. Serotonin 2c polymorphism has also been linked to diabetes in humans. If what we see in animals also work in humans I expect diabetic obese patients will have a 1.0% reduction in HgA1c when Bloom-DM data is out. A diabetic drug is automatically a blockbuster and people can forget about insurance companies not covering an anti obesity drug.
Market Data 
Markets 
AI
